female

(redirected from Female sexual arousal disorder)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Female sexual arousal disorder: Hypoactive sexual desire disorder, Sexual aversion disorder

female

noun female being, female gender, female sex, gender, girl, her, herself, lady, miss, mrs., ms., she, woman
Associated concepts: women's rights
Foreign phrases: Feme, Femme.A woman. Feme covert. Amarried woman. Feme sole. A single woman.
References in periodicals archive ?
Additionally, the company has been selected to present its results from a study entitled, "Use of Standardized Visual Sexual Stimulations (VSS) for in-Clinic Evaluation of Pharmacologic Treatment of Female Sexual Arousal Disorder," at the Western Sectional American Urological Association Meeting in Kauai, HI this October.
Sexual Outcomes in Women Treated With Viagra or Placebo Increased Increased Gential Sexual Sensation Satisfaction All women with female sexual Viagra 57% 42% arousal disorder Placebo 44% 28% Women with female sexual arousal disorder but not hypoactive sexual Viagra 59% 50% desire disorder Placebo 41% 21% Source: Laura Berman, Ph.
1) Female sexual arousal disorder is defined as a persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate lubrication-swelling response of sexual excitement.
AFUD defines Female Sexual Arousal Disorder (FSAD) as the persistent or recurrent inability to attain or maintain sufficient sexual excitement, causing personal distress.
A thorough, time-consuming history will need to be taken to determine which of the common specific dysfunctions is involved: hypoactive sexual desire disorder, female sexual arousal disorder, female orgasmic disorder, dyspareunia, or vaginismus, William D.
NexMed has several alprostadil-based treatments under development, including Vitaros([R]), for the treatment of erectile dysfunction; Femprox([R]), for female sexual arousal disorder, and RayVa([TM]), for Raynaud's syndrome.
The multicenter study, which was conducted in Canada, Europe, and Australia, involved premenopausal and postmenopausal women who were taking hormone replacement therapy and had been diagnosed with female sexual arousal disorder, one of several categories that fall under the broad heading of sexual dysfunction, Dr.
NexMed is also developing a proprietary product pipeline based on its NexACT[R] drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder and an early stage treatment for psoriasis.